NEW YORK (GenomeWeb) – Oxford Immunotec has agreed to acquire substantially all of Imugen's assets in a transaction worth $22.2 million in cash.

The purchase price represents approximately twice Imugen's calendar-year 2015 revenues. Oxford expects to close the deal on July 1.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.

A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.

Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.

In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.